PURPOSE: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC).
METHODS: Patients with advanced RCC and ≤ 1 previous targeted therapy were treated.
RESULTS: Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common.
CONCLUSIONS: Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.
Written by:
Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Greco F. Are you the author?
Sarah Cannon Research Institute, Nashville, TN 37203, USA.
Reference: Cancer Invest. 2013 Jun;31(5):323-9.
doi: 10.3109/07357907.2013.789900
PubMed Abstract
PMID: 23614653
UroToday.com Renal Cancer Section
